Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	40.97B
Revenue (ttm)	3.80B
Net Income (ttm)	919.44M
Shares Out	595.20M
EPS (ttm)	1.55
PE Ratio	44.46
Forward PE	35.30
Dividend	1.50 (2.18%)
Ex-Dividend Date	Jun 11, 2025

Volume	7,448,871
Average Volume	14,237,062
Open	68.36
Previous Close	68.33
Day's Range	68.20 - 69.35
52-Week Range	40.40 - 82.25
Beta	0.89
RSI	42.33
Earnings Date	Oct 31, 2025

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,245
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.